Skip to main content

Ros Matthew E's Form 4 filing

Jasper Therapeutics, Inc. (JSPR) · filed Jul 22, 2026

Accession no.
0001213900-26-080525
Filed
Jul 22, 2026, 7:10 PM ET
Trade date
Jul 20, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 derivative transaction. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ros Matthew ECIK 0001461613Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 20, 2026Voting Common StockPPurchaseAcquired+53,741–F1,F2–881Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026.

Referenced by the price of 1 transaction in Table II.

F2

On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)